Androgen deprivation therapy is the established therapeutic approach for metastatic prostate cancer (PCa), which is acquired either through administering gonadotrophin-releasing hormone (GnRH) agonist (medical castration) or through surgical intervention (bilateral orchiotomy), with or without antiandrogens.1 Similarly, ADT is also coupled with radiotherapy for the management of non-metastatic but locally advanced or high risk prostate cancers.2 The gene discussed is GNRH1; the disease is posterior cortical atrophy.